39 results on '"Gehrs, Leah"'
Search Results
2. A mouse model of Zhu-Tokita-Takenouchi-Kim syndrome reveals indispensable SON functions in organ development and hematopoiesis
3. Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma
4. A mouse model of ZTTK syndrome reveals indispensable SON functions in organ development and hematopoiesis
5. Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial
6. POSTER: AML-080 Modeling Flotetuzumab-Associated Cytokine Release Syndrome (CRS) in AML Using In Vitro and In Vivo Preclinical Models
7. AML-080 Modeling Flotetuzumab-Associated Cytokine Release Syndrome (CRS) in AML Using In Vitro and In Vivo Preclinical Models
8. Data from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
9. Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
10. Table S4 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
11. Table S3 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
12. Data from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
13. Table S1 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
14. Table S4 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
15. Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
16. Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
17. Supplementary Figures from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
18. Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
19. Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
20. Table S3 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
21. Table S1 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
22. Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
23. Supplementary Figures from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
24. Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
25. Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models
26. Optimized Small Molecule VLA-4 Inhibitors for Hematopoietic Stem and Progenitor Cell Mobilization
27. Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma
28. CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells
29. A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
30. A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
31. A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes
32. Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma
33. Abstract 5699: AMV564, a bivalent, bispecific T-cell engager, depletes myeloid-derived suppressor cells and activates T cells in cancer patients
34. Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post–allogeneic hematopoietic stem cell transplant patient
35. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease
36. Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells
37. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
38. An Off-the-Shelf™ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies
39. Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.